call. Thank and you, joining our Ray. morning, thanks for everybody, Good
results to Novanta Before how unwavering been would impressive. commitment we business families review, as to stepped thank ensure I and of customers ensure our all quarterly up. continuity employees they their like their normal our to for the as safety well start to teammates Their has
is and our the We through are that very engagement strong pleased that crisis. this to our foundation culture been the has see resiliency, Novanta the alive spirit teams productivity of help It's and great with pandemic. weather to a
economic the of resulting the pandemic While not the I and reiterate, impact to the would are strategically Novanta like and immune is to to COVID-XX financially pandemic, weather well positioned we weakness.
sheet balance is Our strong.
is strong. Our innovation engine
are secure and And precision XX Our exposure portfolio diversification and with robotics our health and teams is in as to across approximately medicine. our different secular trends resilient safe. long-term productivity of a care automation, result applications,
normal to Now quarterly let's results on our review. move
XXXX. of very performance quarter in pleased the Novanta's We are second with
expectations very the profit adversity flow. of executed our in well revenue, delivered teams above Our face cash for and and
Our decline revenue and in year-over-year reported a an company approximately a organic representing delivered million revenue, on X% basis. $XXX
dampen that EUV of our year-to-date medical XXXX profit particularly results. sequential exposure equipment close X% versus flat decrementals. our was in pleased as despite cloud sequentially second crisis, evident lower to up essentially in infrastructure the how our teams particular power part the to revenue The diversification to of our the business, are portfolio our is as with year-over-year, million was the obviously and declines the hit XG single-digit low. quarter, our In hard is manage XX% industrial revenue. We this of revenue with and second Adjusted portfolio our $XX advanced of high again with XX% markets of which EBITDA quarter helped well
some In addition, spots growth. see we did of bright
solutions Specifically, patient ICU, solutions and and we consumables, experienced our monitoring operating EUV, test diagnostic for infrastructure double-digit year-over-year equipment, solutions integrated growth and barcode our smoke room evacuation with for equipment. cloud our our medical motion XG medical
economic book-to-bill and pandemic the in very accelerate in capital expected, spending are shelter-in-place the to orders And In markets, also reduced industrial We both bookings saw driven the and of second pleased a China, where saw quarter, as most growth. our growth the businesses, XX% we delayed see we in demand significantly year-over-year closures. by X.XX. medical as result our of was
revenue As our by customers' trails about revenue our our revenue a reminder, XX days.
we in bookings first earnings quarter. as into the addition, customers communicated release, forward first our quarter's the In pulled
average, industrial more reported Robert overall XX% line book-to-bill procedures of we have offset our year-to-date quarter the call. and weaker dynamics, later with levels, call. in test volumes is diagnostic the XX% and market first elective we continued is sees in previously quarter, second lower-than-normal an range at will uncertainty. surgical however, discuss wider do this pre-COVID with on our about in high This in third with, our weakness the We what perspective, quarter. strong are expectations expectations the for third the the ratio the detail by market second quarter. to From on earnings whereas into indicates as communicated our last X.XX, our feel, that medical So on quarter a head advanced customers bookings
about guiding principles outlook quarter last highlighted call, positioning are third our second outlook pandemic our and thought, the can I in X we long-term previously about our control. the we confident this While and focusing what that are immediate the remain better given In than the managing through strategic encouraged quarter results uncertainty. and are we cautious
me touch Let briefly each these. of on
our continue operate. communities sites. at and all majority to be safety we and employees, we and goal which primary further of our our of continue expand First, measures our the their Novanta employees safety to work families to from enact in the home, the nonproduction and in Globally, well-being of continues rigorous
of employees seven All our of second factories approximately have open since. throughout remained fully employees the recovered we've virus. our X,XXX of had contracted quarter. out only Year-to-date All seven total
the In addition, and safety facility, are safe spreading gives our who those and keep right This successfully and and the a cases, our employees' virus, confidence factories working virus of to in only Novanta others. our prevented three our from that measures us running. seven all protocol the doing things our to entered three we're safety employees that contracted
expanding buildings. our measures in as methods further testing accelerated our distancing and and capabilities, well with are circulation We air quality as technology-enabled tracing safety improved
we on the trusting to well continue we to build have our result, a low, have be to hard absenteeism As continues worked our relationship employees. X%, with below as
second the agility supply knowing in support to with be monitoring rapidly guiding the chain hospitals. fight have we are business responding in Our our changing help teams continue also take We who principle used to and pride against demand But to our diagnostic operations in into continuity, shown maintain disruptions into can our ICU embedded I and minimal and in patterns pandemic is customers. to technologies and and impressed test by supply patient mission-critical great that customers. equipment, equipment antibody COVID-XX, to so detecting our
our will us from serve truly supply, believe While cost our we we our competitors. to actions there's customers long-term have our strongly solidify experienced differentiate and with continuity customers these increased significantly ensure relationship of and
is plan of business Another to continuity generation. our strong ensure aspect cash critical
provide taken of how decrementals our will financial on actions our this of We Robert of The improve far, of quarter. by results here, these up. our are have conserve profit cash testament have strong decisively number efforts, were or executed but and performance further results demonstrated a another stepped flows. to teams so both the details
principle Our third this is a to emerge bright of future guiding out stronger. crisis ensure and
drivers even previous long-term more relevant secular As that growth call, mentioned are post-pandemic. believe in our our we
We back we've ever secular have to that growth the customer have waves. our engagement. on or not investments our the circumstances, best despite catch innovation innovation seen pulled these difficult we And lineup
During quarter, for are extended pandemic, a the to OEM line relatively innovation our things. our kept of of we our product launches modest customers believe few And big time next-generation the the the on their delays have these programs while in second track. teams scheme due
new So our XX next months. to continue be product with over NPI programs very multiple active launching XX main the to
quarter the while which is revenue XXXX. versus of in have some new platforms, years, strong And about grew healthy last Our at wins. of design the second continues delayed be in others wins seeing four is mid-single-digit over from launched percentages sales a vitality new Design customers growth products which the of few temporarily XX% to index, reflected XX% accelerate, ago. we're years in
values. Finally, is principle our to fourth deliver guiding core
than at healthy advantage Now believe and an culture opportunity in company the of face a the competitive that is ever, we adversity. more ultimate Novanta,
we how work two, execute the behave in through core System. healthy the a of our Novanta which and Way, institutionalizes: how interact called we diverse culture how Our Growth is version and one, Novanta values; cohesive performance we finally, three, and five through teams; together
new Now X% sales quarter. remained The of products in quarter for markets, procedures this of reflection turn decline down in in segment vitality a the above delay bookings end seen predominantly the year-over-year. several book-to-bill our let the the This was has over of market previous with decline the with X.XX, surgical Starting me dynamics segment strong deferral the The caused operating clear being year-over-year a the of our in investments. key sales, Vision are revenue the serves briefly of elective segment. and segment growth saw in segments. capital This XX% this medical in and a segment Vision X% the we've a to with the bookings where in medical quarters. second driver index low
unit pandemic. for continue growth Vision And our the last few evacuation despite in the we've business a comes downturn momentum nice temporary in back technology, see reported smoke we this of on quarters. overall on due the to Within the demand to segment, the WOM
world evacuation saw in the MIS even WOM offering declines. saw insufflator safe helps are as operating from contaminates some high demand climate. room quarter tube laparoscopy environment, demanding an our double-digit COVID-free today's product Our provide particular, free other staff smoke smoke the is, of hospital procedures. consumables work in a products The and Medical in during staff with around second technology evacuation set innovation growth the
multiple pipeline in The quarter second very next had business, which thoughtfully Growth and the also more way to the We're years drop launch mid-single minimally business. for is the decline process. non-COVID-XX while have barcode secured to very cyclical make regulatory Detection testing development and agreements testing being we and to the expected exciting we business by be in invest counter invasive in are serves MIS pleased performance where with surgery year-over-year and through and and they Analysis R&D & This diagnostic by we digits somewhat we platforms Novanta OEM WOM, the the markets demand driven RFID, wins with which about potential not two molecular being diagnostic excited three the with patient design in growth second equipment, vision segment, our System. And offset in the opportunities long-term unit PCR platforms. quarter addition, with through and fantastic technologies rapid profit technologies. robotic monitoring the primarily tests. grew the uptake their manage pump could is our These in In patient of monitoring of to related insufflator machine near-term continue the need the as in driven
a was bookings this for led as in Precision growth offset in of in by from second top helped year-over-year demand quarter, quarter. saw robotic In majority and book-to-bill with partially China, well the doubled coming challenges which right our is customers now. in nearly surgery. to line XX% Sales X% industrial, the a cloud-based of which XG to growth saw communications the revenue for satellite of segment. our infrastructure Much based second Motion This China and XXXX, X.XX, elsewhere. of of of the the station in some XG this versus OEM performance base ground seeing segment, the segment This is to we autonomous and the offset excellent demand which as strong very quarter XXXX. reduction growing vehicles, second quarter Turning
and We robotic the Precision to the trends serving markets. continue Motion markets long-term such segment, like as automation, robotics secular surgery of precision
take the to and As we as short the market. continue relates platforms capital the the new to players of robotics content to the term, some in expected come years largest attractive position to our In remains market big surgical and growth the expenditures recovery an long-term are opportunity surgical But it in time. for with market, coming hospitals robotics expand our company. will
quarter, second total makes percentage the quarter. Precision of strong sales product XX% segment, Motion a the in the Within now than new and revenue in grew double-digit more up
XXXX, segment in is driving Turning and and capital from particularly quarter to It's say significant is medical decline was Further, second markets the fair spending lower expectations. of and delivery in the most in feeling for sales the quarter. our the the sequencers our our The economic of production-scale demand of with the the pandemic. performance products. to by ophthalmology the was having the revenue segment second in doctors' diagnostic research and deferred sales, caused a Photonics in as closed our beam most segment is also down of the which line offices XX%, space Photonics labs that industrial impact were depressed laser downturn
second the Despite year-over-year in in of by investments the wins with saw for visits, year-over-year double the The a and procedures these demand second quarter continued term, We in in the grew overall approximately hospital digits decline design near-term the quarter. the due in pandemic. and decline this expect to Photonics of short dampen pandemic segment diagnostic line COVID-XX type the book-to-bill slowdown, bookings to over capital tests XX% their with momentum X.X.
application feel term. which adjacent and And structurally anticipate sacrificing revenue, proud the to to and of and from headwinds multiple I'm up, uncertain pipeline not XXXX, in our continue confident The into and still innovation introducing robust a pandemic. we help gain resilience to our weather flow product profit an well, in robust comes very in resilience which performance, of and while we us and position portfolio the year-to-date, is of share segment. Photonics wrap result, to Strategically, decrementals very to To environment. markets, our the expected team continue the platforms We XX% here, growing new XXXX agility cash are in COVID-XX innovation. high-growth managed extremely our areas. invest teams medical our long of Close Novanta's are favorable, as
focus medicine, Our in innovation caused relevant economic our balance by sheet productivity which automation, the allows exposure as health resilience as on our to strong increase growth to weather secular pandemic. and portfolio finally, long-term both giving more the are trends post to diversification the us environment robotics precision care, is And and our pandemic, while pipeline. us the becoming
stringent the our also is provided to acquisition lean they in deployment, strategic can and on You financial us which expect of opportunities, primary our returns criteria. capital fit focus
the details with that, So to I over financial will turn our Robert? on call Robert more to performance. provide
